Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism
Status:
Unknown status
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
The primary aim of this study is to evaluate whether mid dose (safe dose) of Alteplase in
addition to standard treatment with heparin (LMWH) in patients with pulmonary embolism (PE)
at intermediate risk, it is effective to reduce:
- right ventricular dysfunction
- pulmonary hypertension 24 hours and 7 days after the treatment
- PE recurrence to 7days and 30 days after the treatment without increasing the incidence
of bleeding intra-extracranial